研究单位：[1]TransThera Sciences (Nanjing), Inc.[2]Anhui Provincial Hospital,Hefei,Anhui,China[3]Peking Union Medical College Hospital,Beijing,Beijing,China[4]Fujian Cancer Hospital,Fuzhou,Fujian,China[5]Zhujiang Hospital of Southern Medical University,Guangzhou,Guangdong,China[6]Shenzhen Qianhai Shekou Free Trade Zone hospital,Shenzhen,Guangdong,China[7]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China[8]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China[9]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,210000[10]Henan Cancer Hospital,Zhengzhou,Henan,China[11]Hubei Cancer Hospital,Wuhan,Hubei,China[12]Zhongnan hospital of Wuhan University,Wuhan,Hubei,China[13]Hunan Cancer Hospital,Changsha,Hunan,China[14]Hunan Cancer Hospital,Changsha,Hunan,China[15]Hunan Provincial People''s Hospital,Changsha,Hunan,China[16]Nanjing Drum Tower Hospital,Nanjing,Jiangsu,China[17]Jilin Cancer Hospital,Changchun,Jilin,China[18]Liaoning Cancer Hospital,Shenyang,Liaoning,China[19]Central Hospital Affiliated to Shangdong First Medical University,Jinan,Shandong,China[20]Shandong Cancer Hospital,Jinan,Shandong,China[21]Eastern Hepatobiliary Surgery Hospital,Shanghai,Shanghai,China[22]Shanxi Cancer Hospital,Taiyuan,Shanxi,China[23]Sichuan Cancer Hospital,Chengdu,Sichuan,China[24]Yunnan Cancer Hospital,Kunming,Yunnan,China[25]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China[26]Beijing Cancer Hospital,Beijing,China,100142[27]Beijing Cancer Hospital,Beijing,China[28]Beijing Tsinghua Changgeng Hospital,Beijing,China[29]Fudan University Shanghai Cancer Hospital,Shanghai,China[30]Zhongshan Hospital,Shanghai,China[31]Tianjin medical university cancer institute & hospital,Tianjin,China
研究目的：
A phase II, open-label, multicenter study to evaluate the efficacy and safety of oral TT-00420 (Tinengotinib) tablets in subjects with cholangiocarcinoma who failed or relapsed to prior treatment of chemotherapy and FGFR Inhibitor.
